Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive disease-modifying drugs, a new study has found. Uncertainty about the impact of these drugs during pregnancy ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

Cenrifki prevents MS disease progression and Itvisma delivers a healthy gene-to-cell nuclei, addressing the root cause of SMA.

Women with multiple sclerosis (MS) are significantly less likely than men to be treated with disease-modifying therapies (DMTs) and highly effective DMTs (HE-DMTs), a new study showed. At comparable ...

Medicaid coverage of highly effective disease-modifying therapies for MS varies widely across the U.S., with no coverage in ...

Add Yahoo as a preferred source to see more of our stories on Google. Out-of-pocket costs for drugs for neurologic diseases such as MS, Parkinson's and Alzheimer's disease are climbing sharply, ...

Nearly one in five stable MS patients developed significant radiological inflammation after stopping first-line treatment. The median time to disease activity after discontinuing treatment was 12 ...

Multiple sclerosis (MS) treatment could be on the brink of a significant breakthrough thanks to innovative research by Immunic Therapeutics. Speaking to Fierce Pharma, CEO Daniel Vitt shares insights ...

People with multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, and that amount soared to $2,378 annually in 2021, according to a new study. The study examined the ...

MS treatments during pregnancy do not seem to increase the risk of neurodevelopmental disorders in exposed children, a study ...

Dublin, April 13, 2026 (GLOBE NEWSWIRE)-- The "Multiple Sclerosis - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on over ...

A person battling multiple sclerosis spent an average of $750 in out-of-pocket fees on medicines in 2012, but by 2021 that same patient spent $2,378 annually, a new report finds. Out-of-pocket costs ...